Härdter Nicole, Geidobler Raimund, Presser Ingo, Winter Gerhard
Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.
Boehringer Ingelheim Pharma GmbH & Co. KG, Pharmaceutical Development Biologicals, 88397 Biberach an der Riß, Germany.
Pharmaceutics. 2023 Dec 15;15(12):2783. doi: 10.3390/pharmaceutics15122783.
Microwave-assisted freeze-drying (MFD) offers significant time savings compared to conventional freeze-drying (CFD). While a few studies have investigated the stability of biopharmaceuticals with low protein concentrations after MFD and storage, the impact of MFD on high-concentration monoclonal antibody (mAb) formulations remains unclear. In this study, we systematically examined the effect of protein concentration in MFD and assessed protein stability following MFD, CFD, and subsequent storage using seven protein formulations with various stabilizers and concentrations. We demonstrated that microwaves directly interact with the active pharmaceutical ingredient (API), leading to decreased physical stability, specifically aggregation, in high-concentration antibody formulations. Furthermore, typically used sugar:protein ratios from CFD were insufficient for stabilizing mAbs when applying microwaves. We identified the intermediate drying phase as the most critical for particle formation, and cooling the samples provided some protection for the mAb. Our findings suggest that MFD technology may not be universally applicable to formulations well tested in CFD and could be particularly beneficial for formulations with low API concentrations requiring substantial amounts of glass-forming excipients, such as vaccines and RNA-based products.
与传统冷冻干燥(CFD)相比,微波辅助冷冻干燥(MFD)可显著节省时间。虽然有一些研究调查了MFD及储存后低蛋白浓度生物制药的稳定性,但MFD对高浓度单克隆抗体(mAb)制剂的影响仍不清楚。在本研究中,我们系统地研究了MFD中蛋白质浓度的影响,并使用七种含有不同稳定剂和浓度的蛋白质制剂,评估了MFD、CFD及随后储存后的蛋白质稳定性。我们证明,微波与活性药物成分(API)直接相互作用,导致高浓度抗体制剂的物理稳定性下降,特别是聚集。此外,在应用微波时,CFD中通常使用的糖与蛋白质比例不足以稳定mAb。我们确定中间干燥阶段是颗粒形成的最关键阶段,对样品进行冷却可为mAb提供一定保护。我们的研究结果表明,MFD技术可能并非普遍适用于在CFD中经过充分测试的制剂,对于需要大量玻璃形成赋形剂的低API浓度制剂(如疫苗和基于RNA的产品)可能特别有益。